Themis Medicare Limited Share Price NSE India S.E.

Equities

THEMISMED

INE083B01024

Pharmaceuticals

Market Closed - NSE India S.E. 05:13:50 03/05/2024 pm IST 5-day change 1st Jan Change
215.1 INR -0.97% Intraday chart for Themis Medicare Limited -0.60% +0.66%
Sales 2022 3.95B 47.34M Sales 2023 3.54B 42.51M Capitalization 10.73B 129M
Net income 2022 729M 8.75M Net income 2023 569M 6.83M EV / Sales 2022 2.33 x
Net Debt 2022 595M 7.13M Net Debt 2023 798M 9.58M EV / Sales 2023 3.25 x
P/E ratio 2022
11.8 x
P/E ratio 2023
18.9 x
Employees 996
Yield 2022
0.54%
Yield 2023
0.43%
Free-Float 21.11%
More Fundamentals * Assessed data
Dynamic Chart
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Themis Medicare Limited Launches REMITHEM CI
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Themis Medicare Limited Announces Incorporation of Wholly Owned Subsidiary CI
Themis Medicare Limited Announces Cessation of Vijay Agarwal as Independent Director CI
Themis Medicare Limited Appoints Reena Patel as Alternate Non-Executive Non- Non-Independent Director to Dr. Adam Demeter, Effective September 11, 2023 CI
Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Themis Medicare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Themis Medicare Limited Announces Board Resignations CI
Themis Medicare Gets Drug Controller General of India’s No-Objection for Diclofenac Injection MT
Themis Medicare Announces DCGI Approval of Remifentanil Hydrochloride 1mg/2mg for Injection for Import and Marketing CI
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Themis Medicare Launches Drug for Treatment of Menopausal Symptoms in India MT
Themis Medicare Ltd. Launches Lenzetto ¡Global Brand of Estradiol Novel Drug Delivery System CI
More news
1 day-0.97%
1 week-0.60%
Current month-2.54%
1 month-5.30%
3 months-6.48%
6 months+36.40%
Current year+0.66%
More quotes
1 week
212.50
Extreme 212.5
228.85
1 month
203.00
Extreme 203
234.35
Current year
194.00
Extreme 194
263.85
1 year
132.61
Extreme 132.605
263.85
3 years
37.72
Extreme 37.72
263.85
5 years
13.83
Extreme 13.83
263.85
10 years
6.15
Extreme 6.15
263.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 29/04/29
Director of Finance/CFO - 01/16/01
Chairman 75 01/73/01
Members of the board TitleAgeSince
Chief Executive Officer 49 29/04/29
Chairman 75 01/73/01
Director/Board Member 70 01/77/01
More insiders
Date Price Change Volume
03/24/03 215.1 -0.97% 21,092
02/24/02 217.2 -1.59% 25,534
30/24/30 220.7 -2.00% 30,514
29/24/29 225.2 +4.07% 79,312
26/24/26 216.4 +2.97% 44,101

Delayed Quote NSE India S.E., May 03, 2024 at 05:13 pm IST

More quotes
Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.
Calendar
More about the company